Nektar Therapeutics (NKTR) Misses Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $72.67 -0.48%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
ELWT, CAAP, RNW, More
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
ELWT, CAAP, RNW, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $37.5 million versus the consensus estimate of $40.85 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Infleqtion raises Q2 revenue to $13.5M after contract restatement
- BofA Securities Downgrades Autohome Inc. (ATHM) to Underperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
